03363nam a2200241   4500001000700000010001500007100004100022101000800063200013900071210008300210215001800293225002500311300009600336330245700432606004102889606002502930606002602955606002202981606002803003606000903031606002103040710006003061384278  a9291681687  a20070514d2004       y0pory50      ba  aeng  aHepatitis C and injecting drug useeimpacts, costs and policy optionsfEuropean Monitoring Centre for Drugs and Drug Addiction, EMCDDA  aLuxembourgcOffice for Official Publications of the European Communitiesd2004  a389 p.d24 cm  aEMCDDA Monographsv7  aTambém disponível em formato pdf através de: https://www.emcdda.europa.eu/?nnodeid=428  aForeword (Georges Estievenart). General introduction (Wien Limburg; Lucas Wiessing; Johannes Jager). Part I - Natural history, treatment, quality of life, epidemiology and prevention: introduction. Chapter 1 - Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview (Wien Limburg). Chapter 2 - Recent developments in hepatitis C diagnostics and treatment (Thierry Poynard). Chapter 3 - Hepatitis C and quality of life (Graham Foster). Chapter 4 - Surveillance of hepatitis C infection among injecting drug users in the European Union (Lucas Wiessing; Kirsty Roy; David Sapinho; Gordon Hay; Avril Taylor; David Goldberg; Richard Hartnoll). Part II - Models of hepatitis C, injecting drug use and policy options: Introduction. Chapter 5 - Modelling the transmission of hepatitis C in injecting drug users (Mirjam Kretzschmar; Lucas Wiessing). Chapter 6 - Modelling injecting drug use and hepatitis C in injecting drug users (Carla Rossi; Nicolina Esposito). Chapter 7 - Modelling policy options to control problem drug use (Gernot Tragler). Part III - Healthcare costs of drug-related hepatitis C infection: introduction. Chapter 8 - Updated healthcare cost estimates for drug-related hepatitis C infections in the European Union (Maarten Postma; Lucas Wiessing and Johannes Jager). Chapter 9 - Cost-effectiveness of treatment of hepatitis C in injecting drug users (John Wong; Diana Sylvestre; Uwe Siebert). Part IV - Wider costs of drug use: introduction. Chapter 10 - Assessment of the indirect costs of injecting drug use: which methods should be employed? (Robert Welte; Hans-Helmut König; Johannes Jager; Reiner Leidl). Chapter 11 - Models to compute the costs to society of injecting drug use and related morbidity (Fernando Antoñanzas; Roberto Rodríguez; María Velasco). Chapter 12 - Assessing the tangible and intangible costs of illicit drug use. Chapter 13 - Social costs of drug use in France (Pierre Kopp; Nicolas Blanchard). Part V - Cost-effectiveness of needle and syringe programmes and methadone maintenance: introduction. Chapter 14 - Cost-effectiveness of needle and syringe programmes: a review of the literature (Ardine de Wit; Jasper Bos). Chapter 15 - The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C (Harold Pollack; Robert Heimer). General conclusions (Lucas Wiessing; Wien Limburg; Johannes Jager). Contributors. Abbreviations.  aPREVENÇÃO DA TOXICODEPENDÊNCIA  aDOENÇA INFECCIOSA   aPOLÍTICA DE SAÚDE  aPOLÍTICA SOCIAL  aPOLÍTICA ORÇAMENTAL  aOEDT  aUNIÃO EUROPEIA  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION